Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients

Inclusion Criteria: * Signed Written Informed Consent * Age≥ 17 and \<80 years, * Newly diagnosed T2DM (defined as T2DM diagnosed within 6 months prior to enrollment) * Oral antidiabetic agents naïve (defined as without receiving any anti-diabetic medication therapy before, or having received anti-diabetic medication ≤ 14 days but not received any antidiabetic medication within the last 1 month prior to enrollment) * HbA1c ≥ 7.0% and ≤10.0% Exclusion Criteria: * Women of child bearing potential * body mass index (BMI)≥35 Kg/m2 or BMI \<18.5 Kg/m2 * Hemoglobin A1c (HbA1c)\>10.0% or \<7.0% * Active liver disease and/or significant abnormal liver function * Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma * Congestive heart failure defined as New York Heart Association (NYHA) class III or IV and /or left ventricular ejection fraction ≤40% * Significant cardiovascular history with the past 6 months * Severe retinopathy, persistent uncontrolled hypertension (SBP≥180mmHg, or DBP≥105mmHg) * Severe chronic gastrointestinal disease * History of alcohol abuse or illegal drug abuse within the past 12 months * Diagnosed anemia * Creatine kinase ≥3 X ULN * Serum creatinine ≥1.5 mg/dL(133μmol/L) \[males\], ≥1.4 mg/dL(124 μmol/L)\[females\] * Alanine amino transferase (ALT) and/or aspartate amino transferase (AST)\> 1.5 X ULN and/or total bilirubin \> 2 X ULN * Hemoglobin \<12g/dL \[males\], \<11g/dL \[females\] * Allergies and Adverse Drug Reactions * Prohibited Treatments and/or Therapies * Prisoners or subjects who are involuntarily incarcerated * Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness * Subjects decline to participate